Cited by 3,738PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase SignalingMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Oncogenic kinase signalling.

Blume-Jensen, Peter, Hunter, Tony·2001·Nature

DOI 10.1038/35077225

Open this paper in CoChat — free account

Abstract

Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans. Their activity is normally tightly controlled and regulated. Perturbation of PTK signalling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation. The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signalling. This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signalling in human malignancies.

Integrity signals

Registry

Crossref · 10.1038/35077225

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,487
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
STATs and Gene Regulation
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Signaling—2000 and Beyond
Hunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Self-citation

Show all 93 references

Research works printed but not linked: 3

Blume-Jensen, P. & Hunter, T. in Encyclopedia of Cancer (ed. Bertino, J. R.) (Academic, San Diego, in the press).
Blume-Jensen, P. & Hunter, T. in Cancer Research - An Encyclopedic Reference (ed. Schwab, M.) (Springer, in the press).
Blume-Jensen, P. & Hunter, T. in Encyclopedia of Cancer (ed. Bertino, J. R.) (Academic, San Diego, in the press).

Sorted by citations

Items 501–600 of 1,008

The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Tefferi, A., & Gilliland, D. G. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.7.947 · Cited by 119
Split-luciferase complementary assay: applications, recent developments, and future perspectives
Azad, T., Tashakor, A., & Hosseinkhani, S. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7980-8 · Cited by 119
Phosphosignature predicts dasatinib response in non-small cell lung cancer
Klammer, M., Kaminski, M., Zedler, A., Oppermann, F., Blencke, S., Marx, S., Müller, S., Tebbe, A., Godl, K., & Schaab, C. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.016410 · Cited by 118
Anti-angiogenesis target therapy for advanced osteosarcoma
Xie, L., Ji, T., & Guo, W. (2017) · Oncology Reports · doi:10.3892/or.2017.5735 · Cited by 119
The homeostatic role of hydrogen peroxide, superoxide anion and nitric oxide in the vasculature
Costa, T. J. D., Barros, P. R., Arce, C., Santos, J. D., da Silva-Neto, J., Egea, G., Dantas, A. P., Tostes, R. C., & Jiménez‐Altayó, F. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.021 · Cited by 117
Niobium(V) Oxide (Nb2O5): Application to Phosphoproteomics
Ficarro, S. B., Parikh, J. R., Blank, N. C., & Marto, J. A. (2008) · Analytical Chemistry · doi:10.1021/ac800564h · Cited by 120
Novel approaches with targeted therapies in bladder cancer
Joaquim Bellmunt, B., Hussain, M., & Dinney, C. P. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(03)00067-2 · Cited by 119
Mixed signals in heart failure: cancer rules
Hoshijima, M., & Chien, K. R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215380 · Cited by 118
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Zorn, J. A., Wang, Q., Fujimura, E., Barros, T. F., & Kuriyan, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121177 · Cited by 118
Inspecting the Structure-Activity Relationship of Protein Kinase CK2 Inhibitors Derived from Tetrabromo-Benzimidazole
Battistutta, R., Mazzorana, M., Sarno, S., Kazimierczuk, Z., Zanotti, G., & Pinna, L. A. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.08.015 · Cited by 118
Recognition-Domain Focused Chemosensors: Versatile and Efficient Reporters of Protein Kinase Activity
Luković, E., Gonzalez‐Vera, J. A., & Imperiali, B. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8046188 · Cited by 118
Modeling tumor invasion and metastasis in Drosophila
Miles, W. O., Dyson, N., & Walker, J. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006908 · Cited by 128
EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
Faoro, L. N., Singleton, P. A., Cervantes, G. M., Lennon, F. E., Choong, N. W., Kanteti, R., Ferguson, B. D., Husain, A. N., Tretiakova, M., Ramnath, N., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075085 · Cited by 117
Expression of Protein Tyrosine Kinases in Head and Neck Squamous Cell Carcinomas
Ongkeko, W. M., Altuna, X., Weisman, R. A., & Wang‐Rodriguez, J. (2005) · American Journal of Clinical Pathology · doi:10.1309/btln-5wtm-j3pc-nrrc · Cited by 117
NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling
Bradshaw, R. A., Pundavela, J., Biarc, J., Chalkley, R. J., Burlingame, A. L., & Hondermarck, H. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.11.003 · Cited by 117
G Proteins in Cancer: The Prostate Cancer Paradigm
Daaka, Y. (2004) · Science s STKE · doi:10.1126/stke.2162004re2 · Cited by 117
Renal Angiomyolipomas from Patients with Sporadic Lymphangiomyomatosis Contain Both Neoplastic and Non-Neoplastic Vascular Structures
Karbowniczek, M., Yu, J. J., & Henske, E. P. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63843-6 · Cited by 117
A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling
Chen, J., & Fang, Y. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01263-7 · Cited by 119
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 117
The Lipid Raft-Anchored Adaptor Protein Cbp Controls the Oncogenic Potential of c-Src
Oneyama, C., Hikita, T., Enya, K., Dobenecker, M.-W., Saito, K., Nada, S., Tarakhovsky, A., & Okada, M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.026 · Cited by 116
Proteomics: New technologies and clinical applications
Latterich, M., Abramovitz, M., & Leyland-Jones, B. R. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.007 · Cited by 116
Beginnings of a signal-transduction pathway for bioenergetic control of cell survival
Hammerman, P. S., Fox, C. J., & Thompson, C. B. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.09.008 · Cited by 117
Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity
Sakoda, H., Gotoh, Y., Katagiri, H., Kurokawa, M., Ono, H., Onishi, Y., Anai, M., Ogihara, T., Fujishiro, M., Fukushima, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301127200 · Cited by 118
Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column
Imami, K., Sugiyama, N., Kyono, Y., Tomita, M., & Ishihama, Y. (2008) · Analytical Sciences · doi:10.2116/analsci.24.161 · Cited by 115
In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma
Chen, J., Hung, W.-S., Chan, H.-H., Tsai, S., & Sun, H. S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts715 · Cited by 116
Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer
Bistrović, A., Krstulović, L., Harej, A., Grbčić, P., Sedić, M., Koštrun, S., Pavelić, S. K., Bajić, M., & Raić‐Malić, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.061 · Cited by 116
Cellular senescence: a promising strategy for cancer therapy
Lee, S., & Lee, J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.294 · Cited by 117
Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate
Danielpour, D. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.12.027 · Cited by 115
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
Steiner, P., Joynes, C. J., Bassi, R., Wang, S., Tonra, J. R., Hadari, Y. R., & Hicklin, D. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1887 · Cited by 116
New perspectives in arsenic-induced cell signal transduction
Qian, Y. R., Castranova, V., & Shi, X. (2003) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(03)00235-6 · Cited by 113
Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family
Pandey, A., Volkots, D. L., Seroogy, J. M., Rose, J. W., Yu, J., Lambing, J. L., Hutchaleelaha, A., Hollenbach, S. J., Abe, K. Y., Giese, N. A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020143r · Cited by 114
Cell polarity proteins: common targets for tumorigenic human viruses
Javier, R. T. (2008) · Oncogene · doi:10.1038/onc.2008.352 · Cited by 118
Regulation of Insulin-Like Growth Factor Type I (IGF-I) Receptor Kinase Activity by Protein Tyrosine Phosphatase 1B (PTP-1B) and Enhanced IGF-I-Mediated Suppression of Apoptosis and Motility in PTP-1B-Deficient Fibroblasts
Buckley, D. A., Cheng, A., Kiely, P. A., Tremblay, M. L., & O’Connor, R. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.1998-2010.2002 · Cited by 114
CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia
de Menezes, D. E. L., Peng, J., Garrett, E. N., Louie, S. G., Lee, S. H., Wiesmann, M., Tang, Y., Shephard, L. B., Goldbeck, C., Oei, Y. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0358 · Cited by 114
The Phospholipids Sphingosine-1-Phosphate and Lysophosphatidic Acid Prevent Apoptosis in Osteoblastic Cells via a Signaling Pathway Involving Gi Proteins and Phosphatidylinositol-3 Kinase
Grey, A. B., Chen, Q., Callon, K. E., Xu, X., Reid, I. R., & Cornish, J. (2002) · Endocrinology · doi:10.1210/en.2002-220347 · Cited by 114
The EGFR‐GEP100‐Arf6‐AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis†
Sabe, H., Hashimoto, S., Morishige, M., Ogawa, E., Hashimoto, A., Nam, J., Miura, K., Yano, H., & Onodera, Y. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00917.x · Cited by 116
Identification of potent inhibitors of NEK7 protein using a comprehensive computational approach
Aziz, M., Ejaz, S. A., Tamam, N. M., Siddique, F., Riaz, N., Qais, F. A., Chtita, S., & Iqbal, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-10253-5 · Cited by 113
Benzimidazole-biologically attractive scaffold for protein kinase inhibitors
Singla, P., Luxami, V., & Paul, K. (2013) · RSC Advances · doi:10.1039/c3ra46304d · Cited by 111
Identification of Compounds with Nanomolar Binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening
Lyne, P. D., Kenny, P. W., Cosgrove, D. A., Deng, C., Zabludoff, S., Wendoloski, J. J., & Ashwell, S. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030504i · Cited by 113
STI-571: an anticancer protein-tyrosine kinase inhibitor
Roskoski, R. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.055 · Cited by 112
Constitutive activation of PI3K-Akt and NF-κB during prostate cancer progression in autochthonous transgenic mouse model
Shukla, S., MacLennan, G. T., Marengo, S. R., Resnick, M. I., & Gupta, S. (2005) · The Prostate · doi:10.1002/pros.20217 · Cited by 114
Transmembrane Peptides as Inhibitors of ErbB Receptor Signaling
Bennasroune, A., Fickova, M., Gardin, A., Dirrig‐Grosch, S., Aunis, D., Crémel, G., & Hubert, P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-10-0753 · Cited by 113
Growth arrest‐specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway
Sawabu, T., Seno, H., Kawashima, T., Fukuda, A., Uenoyama, Y., Kawada, M., Kanda, N., Sekikawa, A. M., Fukui, H., Yanagita, M., et al. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20211 · Cited by 112
Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention
Hsu, S., Singh, B. B., & Schuster, G. S. (2003) · Oral Oncology · doi:10.1016/j.oraloncology.2003.09.012 · Cited by 113
Proteomics Analysis of Protein Kinases by Target Class-selective Prefractionation and Tandem Mass Spectrometry
Wissing, J. B., Jänsch, L., Nimtz, M., Dieterich, G., Hornberger, R., Kéri, G., Wehland, J., & Daub, H. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t600062-mcp200 · Cited by 112
Site-specific incorporation of phosphotyrosine using an expanded genetic code
Hoppmann, C., Wong, A., Yang, B., Li, S., Hunter, T., Shokat, K. M., & Wang, L. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2406 · Cited by 112
Self-citation
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase
Shim, J., Choi, H. S., Pugliese, A., Lee, S., Chae, J., Choi, B. Y., Bode, A. M., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802200200 · Cited by 112
Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling
Janmaat, M. L., Rodríguez, J. A., Jimeno, J. M., Kruyt, F. A. E., & Giaccone, G. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011361 · Cited by 112
Src continues aging: current and future clinical directions
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111
Simvastatin suppresses breast cancer cell proliferation induced by senescent cells
Liu, S., Uppal, H., Demaria, M., Desprez, P.-Y., Campisi, J., & Kapahi, P. (2015) · Scientific Reports · doi:10.1038/srep17895 · Cited by 124
Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis
Bennett, J. T., Tan, T. Y., Alcantara, D., Tétreault, M., Timms, A. E., Jensen, D. M., Collins, S., Nowaczyk, M. J. M., Lindhurst, M. J., Christensen, K. M., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.02.006 · Cited by 111
Phosphopeptide Fragmentation and Site Localization by Mass Spectrometry: An Update
Potel, C. M., Lemeer, S., & Heck, A. J. R. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04746 · Cited by 116
p21-activated Kinase 1 (PAK1) Interacts with the Grb2 Adapter Protein to Couple to Growth Factor Signaling
Puto, L. A., Pestonjamasp, K. N., King, C. C., & Bokoch, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208414200 · Cited by 111
Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation
Pan, C., Huo, Y., An, X., Singh, G., Chen, M., Yang, Z., Pu, J., & Li, J. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2011.12.006 · Cited by 111
Biology of Aurora A kinase: Implications in cancer manifestation and therapy
Dhanasekaran, K., Prasad, S. B. B., Shandilya, J., Agrawal, S., & Kundu, T. K. (2010) · Medicinal Research Reviews · doi:10.1002/med.20203 · Cited by 111
Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines
Miyake, I., Hakomori, Y., Shinohara, A., Gamou, T., Saito, M., Iwamatsu, A., & Sakai, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205735 · Cited by 111
Successive and Selective Release of Phosphorylated Peptides Captured by Hydroxy Acid-Modified Metal Oxide Chromatography
Kyono, Y., Sugiyama, N., Imami, K., Tomita, M., & Ishihama, Y. (2008) · Journal of Proteome Research · doi:10.1021/pr800305y · Cited by 110
Highly Efficient Phosphoproteome Capture and Analysis from Urinary Extracellular Vesicles
Wu, X., Li, L., Iliuk, A. B., & Tao, W. A. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00459 · Cited by 110
Phosphoinositide 3-Kinase-mediated Reduction of Insulin Receptor Substrate-1/2 Protein Expression via Different Mechanisms Contributes to the Insulin-induced Desensitization of Its Signaling Pathways in L6 Muscle Cells
Pirola, L., Bonnafous, S., Johnston, A., Chaussade, C., Portis, F., & OBBERGHEN, E. V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208984200 · Cited by 110
Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression
Wang, Y., Kelber, J. A., Cao, H. S. T., Cantin, G. T., Lin, R., Wang, W., Kaushal, S., Bristow, J. M., Edgington, T. S., Hoffman, R. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914776107 · Cited by 110
Global Phosphoproteome of HT-29 Human Colon Adenocarcinoma Cells
Kim, J., Tannenbaum, S. R., & White, F. M. (2005) · Journal of Proteome Research · doi:10.1021/pr050048h · Cited by 110
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds
Engel, M., Hindie, V., Lopez-Garcia, L. A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601416 · Cited by 110
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.
Khaleghpour, K., Li, Y., Banville, D., Yu, Z.-B., & Shen, S.-H. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg195 · Cited by 123
A Prototype Antibody Microarray Platform to Monitor Changes in Protein Tyrosine Phosphorylation
Gembitsky, D. S., Lawlor, K., Jacovina, A. T., Yaneva, M., & Tempst, P. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400075-mcp200 · Cited by 110
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B
Lee, S., & Wang, Q. (2006) · Medicinal Research Reviews · doi:10.1002/med.20079 · Cited by 109
Improved Immobilized Metal Affinity Chromatography for Large-Scale Phosphoproteomics Applications
Ndassa, Y., Orsi, C., Marto, J. A., Chen, S., & Ross, M. M. (2006) · Journal of Proteome Research · doi:10.1021/pr0602803 · Cited by 109
Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer
Maria, R. D., Olivero, M., Iussich, S., NAKAICHI, M., Murata, T., BIOLATTI, B., & Renzo, M. F. D. (2005) · Cancer Research · doi:10.1158/0008-5472.907.65.3 · Cited by 108
Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study
Kaur, P., Shukla, S., & Gupta, S. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn201 · Cited by 109
The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors
Chang, W., Lin, R., Yu, J., Chang, W., Fu, C.-H., Lai, A. C., Yu, A. L.-T., & Yu, A. L.-T. (2013) · Breast Cancer Research · doi:10.1186/bcr3423 · Cited by 108
Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression
Bardella, C., Costa, B., Maggiora, P., Patane’, S., Olivero, M., Ranzani, G. N., Bortoli, M. D., Comoglio, P. M., & Renzo, M. F. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0600 · Cited by 108
Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells
Wen, B., Deutsch, É., Marangoni, E., Frascona, V., Maggiorella, L., Abdulkarim, B., Chavaudra, N., & Bourhis, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2171 · Cited by 108
Rab5c promotes AMAP1–PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion
Onodera, Y., Nam, J., Hashimoto, A., Norman, J. C., Shirato, H., Hashimoto, S., & Sabe, H. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201201065 · Cited by 109
Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis
Zheng, X., Song, J., Yu, C., Zhou, Z., Liu, X., Yu, J., Xu, G., Yang, J., He, X., Bai, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00881-8 · Cited by 116
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness
Maggiora, P. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00250-7 · Cited by 107
Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy
Shapiro, P. S. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795538 · Cited by 109
Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Warmuth, M., Damoiseaux, R. D., Liu, Y., Fabbro, D., & Gray, N. S. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454126 · Cited by 111
PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway
Yang, Q., Zhong, S., He, L., Jia, X., Tang, H., Cheng, S., Ren, J., Yu, H., Zhou, L., Zhou, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.028 · Cited by 106
Clinical Applications of Proteomics
Petricoin, E. F., & Liotta, L. A. (2003) · Journal of Nutrition · doi:10.1093/jn/133.7.2476s · Cited by 106
Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase
Abouzid, K. A. M., & Shouman, S. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.038 · Cited by 106
Targeted Molecular Therapy of the PI3K Pathway
Rychahou, P. G., Jackson, L. N., Silva, S. R., Rajaraman, S., & Evers, B. M. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000220040.66012.a9 · Cited by 106
Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epithelium
Schmandt, R. E., Broaddus, R. R., Lu, K. H., Shvartsman, H. S., Thornton, A., Malpica, A. L., Sun, C. C., Bodurka, D. C., & Gershenson, D. M. (2003) · Cancer · doi:10.1002/cncr.11561 · Cited by 106
Prophylactic cancer vaccines
Finn, O. J., & Forni, G. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00317-5 · Cited by 107
Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Kirouac, D. C., Du, J. Y., Lahdenranta, J., Overland, R. P., Yarar, D., Paragas, V. B., Pace, E. A., McDonagh, C. F., Nielsen, U. B., & Onsum, M. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004008 · Cited by 107
Our changing view of the genomic landscape of cancer
Bell, D. W. (2009) · The Journal of Pathology · doi:10.1002/path.2645 · Cited by 109
Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways
Lee, Y. S., Kim, S.-Y., Hong, H. K., Hong, H. K., Lee, Y., Oh, B. Y., Lee, W. Y., & Cho, Y. B. (2016) · Oncotarget · doi:10.18632/oncotarget.9209 · Cited by 105
A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression
Liang, S., Guo, H., Ma, K., Li, X., Wu, D., Wang, Y., Wang, W., Zhang, S., Cui, Y., Liu, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1538 · Cited by 105
Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression
Ide, H., Seligson, D. B., Memarzadeh, S., Xin, L., Horvath, S., Dubey, P., Flick, M. B., Kacinski, B. M., Palotie, A. V., & Witte, O. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222537099 · Cited by 106
Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer
Boffa, D. J., Luan, F., Thomas, D. A., Yang, H., Sharma, V. K., Lagman, M., & Suthanthiran, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0629-3 · Cited by 105
Soy Isoflavones Increase Latency of Spontaneous Mammary Tumors in Mice
Jin, Z., & MacDonald, R. S. (2002) · Journal of Nutrition · doi:10.1093/jn/131.10.3186 · Cited by 105
Catch me if you can: Mass spectrometry‐based phosphoproteomics and quantification strategies
Eyrich, B., Sickmann, A., & Zahedi, R. P. (2011) · PROTEOMICS · doi:10.1002/pmic.201000489 · Cited by 104
The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function
Mattoon, D., Klein, P., Lemmon, M. A., Lax, I., & Schlessinger, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307286101 · Cited by 104
Cellular lifespan and senescence signaling in embryonic stem cells
Miura, T., Mattson, M. P., & Rao, M. S. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00134.x · Cited by 102
MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways
Tiemin, P., Meng, F., Xiao, P., Han, J., Ruipeng, S., Lan, Y., Wang, Y., Junlin, X., Qingfu, L., Zhefeng, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.021 · Cited by 103
Chapter 40 Identification and Quantification of Protein Posttranslational Modifications
Farley, A. R., & Link, A. J. (2009) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(09)63040-8 · Cited by 108
Development And Strategies Of VEGFR-2/KDR Inhibitors
Huang, L., Huang, Z., Bai, Z., Xie, R., Sun, L., & Lin, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.121 · Cited by 103
Inactivation of Platelet-derived Growth Factor Receptor by the Tumor Suppressor PTEN Provides a Novel Mechanism of Action of the Phosphatase
Mahimainathan, L., & Choudhury, G. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314328200 · Cited by 103
Post‐phosphorylation prolyl isomerisation of gephyrin represents a mechanism to modulate glycine receptors function
Zita, M. M., Marchionni, I., Bottos, E., Righi, M., Sal, G. D., Cherubini, E., & Zacchi, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601625 · Cited by 103
Proteomic Contributions to Personalized Cancer Care
Koomen, J. M., Haura, E. B., Bepler, G., Sutphen, R., Remily-Wood, E. R., Benson, K., Hussein, M. A., Hazlehurst, L., Yeatman, T. J., Hildreth, L., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800002-mcp200 · Cited by 105
(–)‐Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor–vascular endothelial growth factor receptor axis
Shirakami, Y., Shimizu, M., Adachi, S., Sakai, H., Nakagawa, T., Yasuda, Y., Tsurumi, H., Hara, Y., & Moriwaki, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01241.x · Cited by 103
EPMA position paper in cancer: current overview and future perspectives
Grech, G., Zhan, X., Yoo, B. C., Bubnov, R. V., Hagan, S., Danesi, R., Vittadini, G., & Desiderio, D. M. (2015) · The EPMA Journal · doi:10.1186/s13167-015-0030-6 · Cited by 104

Authors: Blume-Jensen, P., & Hunter, T.
Affiliations: Salk Institute for Biological Studies (US)
ORCID: Hunter, Tony
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2001-05-01
Volume: 411
Issue: 6835
Pages: 355-365
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/35077225
OpenAlex: W1639582946
Cited by: 3,738
References: 93
Citations by year: 2026: 48 · 2025: 69 · 2024: 87 · 2023: 102 · 2022: 103 · 2021: 114 · 2020: 121 · 2019: 118 · 2018: 105 · 2017: 119 · 2016: 131 · 2015: 156 · 2014: 186 · 2013: 185 · 2012: 200
FWCI: 12.95
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: tyrosine kinase, oncogenic signaling, signal transduction, phosphatidylinositol 3-kinase, Akt, p70 S6 kinase, mTOR, kinase autoinhibition, malignant transformation, human malignancies
MeSH terms: Animals, Humans, Mutation, Neoplasms, Oncogenes, Protein-Tyrosine Kinases, Signal Transduction, Oncogene Proteins, Retroviridae Proteins, Oncogenic, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, Receptor Protein-Tyrosine Kinases, Oncogene Protein v-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oncogenic kinase signalling.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks